ABSTRACT
Oxytocin (OT), the brain’s most abundant neuropeptide, plays an important role in social salience and motivation. Clinical trials of the efficacy of OT in autism spectrum disorder (ASD) have reported mixed results due in part to ASD’s complex etiology. We hypothesized that genetic and epigenetic variation contribute to variable endogenous OT levels that modulate sensitivity to OT therapy. To test this hypothesis, we integrated genome-wide profiles of DNA-methylation, transcriptional activity, and genetic variation with plasma OT levels in 290 participants with ASD enrolled in a randomized controlled trial of OT. Our analysis shows subtle, but statistically significant association of plasma OT levels with peripheral transcriptional activity and DNA-methylation profiles across several annotated gene sets. We also identified genetic variants with novel association with plasma OT, several of which reside in known ASD risk genes. These findings broaden our understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of ASD and its interaction with OT signaling and OT-based interventions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01944046
Funding Statement
The authors disclose receipt of the following sources of financial support for the research, analysis, authorship, and publication described in this manuscript: This work was supported by the NIH through two R01 awards to support the SOARS-B phase 2 clinical trial (RFA-HD 12-196) and the subsequent molecular analysis of the samples from SOARS-B participants (R01-HD-088007) and by the Autism Speaks Weatherstone Fellowship (Grant # 10136).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees at the Duke University School of Medicine, Icahn School of Medicine at Mount Sinai, New York, Seattle Children's Hospital and the University of Washington, Massachusetts General Hospital and Harvard Medical School, Vanderbilt University, Columbia University, and University of North Carolina at Chapel Hill gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author
